Viewing nowPregast capsule 300 mg (Pregabalin)
Pregabalin 300mg
Hard capsule · Prescription medication
Bukwang Pharmaceuticals Co., Ltd.

MFDS item code 201603683 · Approved 2016.06.21 · Insurance code 642204100
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial seizures in epilepsy
This medication is used to treat peripheral and central neuropathic pain in adults. Additionally, it is utilized as an adjunctive treatment for patients with epilepsy experiencing partial seizures, with or without secondary generalized symptoms. It is also effective in treating fibromyalgia. It aims to improve the quality of life for patients with these three primary conditions and symptoms.
This medicine is administered orally as pregabalin, with the total daily dose divided into 2 doses, regardless of food. Since this medicine is excreted primarily by the kidneys, the dose should be adjusted in patients with impaired renal function. (Refer to section ‘5. Patients with Renal Impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: The starting dose of this medicine may be 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may then be increased at 7-day intervals up to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: The starting dose of this medicine may be 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (Refer to section ‘4. Discontinuation of Treatment’) 2. Epilepsy Adults: The starting dose of this medicine may be 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, it may then be increased at 7-day intervals up to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg/day. The starting dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medicine is excreted primarily by the kidneys unchanged. Since the clearance of this medicine is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. *: For women, multiply the result obtained from the above calculation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose determined according to renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function ≥60: Starting dose 150 mg/day, maximum dose 600 mg/day, BID or TID ≥30 -<60: Starting dose 75 mg/day, maximum dose 300 mg/day, BID or TID ≥15 -<30: Starting dose 25-50 mg/day, maximum dose 150 mg/day, QD or BID <15: Starting dose 25 mg/day, maximum dose 75 mg/day, QD Supplemental dose after hemodialysis: Starting dose 25 mg, maximum dose 100 mg, single dose b TID = Total daily dose divided into 3 doses BID = Total daily dose divided into 2 doses QD = Administered once daily a: The total daily dose (mg/day) should be divided as specified in the administration schedule. b: Supplemental dose refers to a dose administered once as an additional dose. 6. Patients with Hepatic Impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly Patients (65 years and older) Dose reduction may be necessary in elderly patients with impaired renal function.
Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12 ~17 years: Administration is not recommended because there are insufficient data on safety and efficacy.
This medication may increase the risk of suicidal thoughts or behaviors, thus careful monitoring for symptoms of depression or mood changes is advised during use. Patients with hypersensitivity to this drug or genetic issues like lactose intolerance should not use it. Diabetic patients may need dosage adjustments for blood sugar control due to weight gain, and if symptoms of angioedema occur, treatment should be discontinued immediately. Elderly individuals may experience dizziness, drowsiness, or loss of consciousness, necessitating caution and consultation with a physician if vision changes occur. Abruptly stopping this medication can induce withdrawal symptoms like insomnia, headache, nausea, and anxiety, hence it should be tapered off gradually under a doctor’s direction. Patients with a history of substance abuse may have a higher risk of misuse, thus should use this medication cautiously and monitor for signs of drug misuse or dependence. Patients with impaired kidney function may require dose adjustments. Patients with heart disease or severe congestive heart failure should use this medication with caution. When used in conjunction with opioid analgesics, there is an increased risk of CNS depression, thus caution is warranted. This medication may cause dizziness and drowsiness, thus hazardous activities like driving or operating machinery should be avoided until the effects are known. During early pregnancy, there may be a risk of fetal malformations, hence pregnant women are advised against using this medication, and women of childbearing age should use effective contraception. Breastfeeding women should consult with a physician regarding whether to discontinue breastfeeding or the medication, as it may pass into breast milk and affect the infant. In case of overdose, symptoms such as confusion, drowsiness, and depression may present, and treatment such as hemodialysis may be necessary. This medication should be kept out of reach of children and should not be transferred to other containers. In the event of serious allergic reactions such as rash, swelling, difficulty breathing, or pain in mucous membranes, the medication should be stopped immediately and medical consultation should be sought.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to prevent exposure to air or moisture, ideally at room temperature between 15 to 30 degrees Celsius. Proper storage will help maintain the medication’s effectiveness over time.
A hard capsule with a reddish-brown upper part and a white lower part containing a white powder that is white or light yellow in color.
30 capsules/bottle, 60 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 300mg
Hard capsule · Prescription medication
Bukwang Pharmaceuticals Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.